Since our in vitro results indicated that LEDGF/p75 overexpression in PCa cells leads to ERp57 upregulation, and that LEDGF/p75 binds to and transactivates the ERp57 promoter, we hypothesized that the expression of both proteins would correlate in human clinical prostate tumors. The gene discussed is PDIA3; the disease is prostate neoplasm.